AbCellera Biologics Inc

For the period ended Mar 31, 2024. Filed May 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

ABCL$12.46-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Loss and Comprehensive

Condensed Consolidated Statements of Loss and Comprehensive Loss

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)

	Three months ended March 31,
	2023	2024
Revenue:
Research fees	$10,570	$9,774
Licensing revenue	372	180
Milestone payments	1,250	-
Total revenue	12,192	9,954
Operating expenses:
Research and development(1)	52,647	39,287
Sales and marketing(1)	3,771	3,365
General and administrative(1)	15,134	17,352
Depreciation and amortization	5,514	4,844
Total operating expenses	77,066	64,848
Loss from operations	(64,874)	(54,894)
Other (income) expense
Interest income	(9,759)	(10,401)
Grants and incentives	(3,374)	(3,275)
Other	(3,593)	1,529
Total other (income)	(16,726)	(12,147)
Net loss before income tax	(48,148)	(42,747)
Income tax recovery	(8,038)	(2,137)
Net loss	$(40,110)	$(40,610)
Foreign currency translation adjustment	(630)	(96)
Comprehensive loss	$(40,740)	$(40,706)
Net loss per share
Basic	$(0.14)	$(0.14)
Diluted	$(0.14)	$(0.14)
Weighted-average common shares outstanding
Basic	287,767,136	292,723,901
Diluted	287,767,136	292,723,901

1 Exclusive of depreciation and amortization

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.